Voyager Therapeutics
Market Cap
US$483.1m
Last Updated
2020/05/24 05:56 UTC
Data Sources
Company Financials +
Executive Summary
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has Voyager Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VYGR's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
9.3%
VYGR
0.7%
US Biotechs
1.8%
US Market
1 Year Return
-46.1%
VYGR
22.1%
US Biotechs
3.7%
US Market
Return vs Industry: VYGR underperformed the US Biotechs industry which returned 22% over the past year.
Return vs Market: VYGR underperformed the US Market which returned 3.7% over the past year.
Shareholder returns
| VYGR | Industry | Market | |
|---|---|---|---|
| 7 Day | 9.3% | 0.7% | 1.8% |
| 30 Day | 16.2% | 4.9% | 5.6% |
| 90 Day | 9.3% | 10.7% | -7.4% |
| 1 Year | -46.1%-46.1% | 23.3%22.1% | 6.1%3.7% |
| 3 Year | 45.0%45.0% | 36.3%31.7% | 28.3%19.8% |
| 5 Year | n/a | -2.5%-8.3% | 52.4%35.1% |
Price Volatility Vs. Market
How volatile is Voyager Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
News Flash: Analysts Just Made An Upgrade To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Forecasts2 months ago | Simply Wall St
Earnings Beat: Voyager Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts5 months ago | Simply Wall St
If You Had Bought Voyager Therapeutics (NASDAQ:VYGR) Shares A Year Ago You'd Have Made 28%Valuation
Is Voyager Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: VYGR ($12.99) is trading below our estimate of fair value ($39.91)
Significantly Below Fair Value: VYGR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: VYGR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: VYGR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VYGR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VYGR is overvalued based on its PB Ratio (6x) compared to the US Biotechs industry average (3.8x).
Next Steps
Future Growth
How is Voyager Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
22.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VYGR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VYGR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VYGR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VYGR's revenue (30.9% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: VYGR's revenue (30.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VYGR is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Voyager Therapeutics performed over the past 5 years?
-14.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VYGR is currently unprofitable.
Growing Profit Margin: VYGR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VYGR is unprofitable, and losses have increased over the past 5 years at a rate of -14.7% per year.
Accelerating Growth: Unable to compare VYGR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VYGR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.3%).
Return on Equity
High ROE: VYGR has a negative Return on Equity (-51.02%), as it is currently unprofitable.
Next Steps
Financial Health
How is Voyager Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: VYGR's short term assets ($272.5M) exceed its short term liabilities ($72.5M).
Long Term Liabilities: VYGR's short term assets ($272.5M) exceed its long term liabilities ($170.3M).
Debt to Equity History and Analysis
Debt Level: VYGR is debt free.
Reducing Debt: VYGR had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VYGR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VYGR has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 6.8% each year.
Next Steps
Dividend
What is Voyager Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VYGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VYGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VYGR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VYGR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VYGR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
G. Turenne (45yo)
1.83yrs
Tenure
US$2,844,090
Compensation
Mr. G. Andre Turenne has been President, Chief Executive Officer and Director at Voyager Therapeutics, Inc. since July 16, 2018. Mr. Turenne has proven leadership, strategic vision, and a strong track reco ...
CEO Compensation Analysis
Compensation vs Market: G.'s total compensation ($USD2.84M) is about average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: G.'s compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.83yrs | US$2.84m | 0.057% $277.7k | |
| Senior VP & General Counsel | 1.08yrs | US$3.34m | 0.017% $81.6k | |
| Chief Medical Officer and Head of Research & Development | 1.33yrs | US$3.82m | no data | |
| Executive Science Advisor & Director | 5.67yrs | US$578.18k | 2.32% $11.2m | |
| no data | no data | no data | ||
| no data | no data | no data | ||
| no data | no data | no data | ||
| no data | no data | no data | ||
| CFO & Principal Accounting Officer | 1.92yrs | no data | 0.021% $102.0k | |
| Chief Technical Operations Officer | 2.5yrs | no data | no data |
1.8yrs
Average Tenure
55yo
Average Age
Experienced Management: VYGR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.83yrs | US$2.84m | 0.057% $277.7k | |
| Executive Science Advisor & Director | 5.67yrs | US$578.18k | 2.32% $11.2m | |
| Consultant & Member of Scientific Advisory Board | 0.92yr | US$1.81m | 0.37% $1.8m | |
| Independent Director | 6.33yrs | US$601.18k | 0.21% $994.9k | |
| Independent Director | 6.92yrs | US$578.18k | 0.099% $476.7k | |
| Independent Director | 3.33yrs | US$591.52k | no data | |
| Independent Director | 4.67yrs | US$597.52k | no data | |
| Independent Chairman | 0.92yr | US$644.18k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.0yrs
Average Tenure
64yo
Average Age
Experienced Board: VYGR's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Voyager Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Voyager Therapeutics, Inc.
- Ticker: VYGR
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$483.107m
- Shares outstanding: 37.19m
- Website: https://www.voyagertherapeutics.com
Number of Employees
Location
- Voyager Therapeutics, Inc.
- 75 Sidney Street
- Cambridge
- Massachusetts
- 2139
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| VYGR | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Nov 2015 |
| VT6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2015 |
| VYGR * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Nov 2015 |
Biography
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company’s lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson’s disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington’s disease; VY-FXN01 for Friedreich’s ataxia; Tau program for the treatment of tauopathies, including Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson’s disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with AbbVie Inc.; the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/24 05:56 |
| End of Day Share Price | 2020/05/22 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.